Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas

Oncotarget

Volumn 6, Issue 41, 2015, Pages 43594-43604

  Smaglo, Brandon G ^a   Tesfaye, Anteneh ^a   Halfdanarson, Thorvardur R ^b   Meyer, Joshua E ^c   Wang, Jue ^d   Gatalica, Zoran ^e   Reddy, Sandeep ^e   Arguello, David ^e   Boland, Patrick M ^f  

^a GEORGETOWN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e CARIS LIFE SCIENCES   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Anal squamous cell carcinoma; Biomarker analysis; Tumor profile

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; THYMIDYLATE SYNTHASE; TUMOR MARKER; TRANSCRIPTOME;

ADULT; ADVANCED CANCER; AGED; ANAL SQUAMOUS CELL CARCINOMA; ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; ANUS TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; POLYMERASE CHAIN REACTION;

ANUS NEOPLASMS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84952948280     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6202     Document Type: Article

References (31)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer J Clin. 2015; 65:5-29.
2. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004; 101: 281-288.
3. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum. 2009; 52: 624-631.
4. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, von Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997; 15: 2040-2049.
5. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L and Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14: 2527-2539.
6. Papaconstantinou HT, Bullard KM, Rothenberger DA, Madoff RD. Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. Colorectal Dis. 2006; 8: 124-129.
7. van der Wal BC, Cleffken BI, Gulec B, Kaufman HS, Choti MA. Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy. J Gastrointest Surg. 2001; 5: 383-387.
8. Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F. 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer. 1999; 86: 861-865.
9. Eng C, Chang GJ, You YN, Das P, Rodriguez-Bigas M, Xing Y, Vauthey JN, Rogers JE, Ohinata A, Pathak P, Sethi S, Phillips JK, Crane CH, Wolff RA. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014; 5: 11133-11142.
10. Lukan N, Ströbel P, Willer A, Kripp M, Dinter D, Mai S, Hochhaus A Hofheinz RD. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009; 77: 293-299.
11. Saif MW, Kontny E, Syrigos KN, Shahrokni A. The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. J Oncol. 2011;2011:125467.
12. Phan LK, Hoff PM. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum. 2007; 50: 395-398.
13. Lê LH, Chetty R, Moore MJ. Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol. 2005; 124: 20-23.
14. Serup-Hansen E, Linnemann D, Hogdall E, Geertsen PF, Havsteen H. KRAS and BRAF mutations in anal carcinoma. APMIS. 2015; 123: 53-59.
15. Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Paris E, Juzyna B, Ezra P, Azria D. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol. 2013; 24: 2834-2838.
16. Olivatto LO, Vieira FM, Pereira BV, Victorino AP, Bezerra M, Araujo CM, Erlich F, Faroni L, Castro L, Lusis EC, Marins A, Ferreira CG. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. 2013; 119: 2973-2980.
17. Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays Biochem. 2011; 50: 209-232.
18. Jiang H, Wang H, Wang S, Pei Z, Fu Z, Fang C, Wang J, Lu Q, Wang E, Li J. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy. Mol Med Rep. 2015; 11: 3523-3532.
19. Subbarayan PR, Sarkar M, Nelson G, Benitez E, Singhal S, Ardalan B. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. Anticancer Res. 2010; 30: 1149-1156.
20. Licitra L, Storkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013; 49: 1161-8.
21. Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, Niazi T, Garant A, Macheto D, Alcindor T, Vuong T. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer. 2012; 107: 1864-1868.
22. Patel H, Polanco-Echeverry G, Segditsas S, Volikos E, McCart A, Lai C, Guenther T, Zaitoun A, Sieber O, Ilyas M, Northover J, Silver A. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. Int J Cancer. 2007; 121: 2668-2673.
23. Sun ZJ, Zhang L, Zhang W, Hall B, Bian Y, Kulkarni AB. Inhibition of mTOR Reduces Anal Carcinogenesis in Transgenic Mouse Model. PLoS ONE. 2013; 8: e74888.
24. Gujja S, Williamson SK, Batra A, Saeed AM, Lai K, Fogel BJ, James JD, Siegel ER, Govindarajan R. Programmed cell death-Ligand 1 (PD-L1) expression and outcome in patients with squamous cell cancer of anal canal (SCCAC). J Clin Oncol. 2015; 33 suppl: ABSTR 3523.
25. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol. 2014; 26: 13-21.
26. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30 Suppl 5: F12-23.
27. Ghosn M, Kourie HR, Abdayem P Antoun J, Nasr D. Anal cancer treatment: current status and future perspectives. World J Gastroenterol. 2015; 21: 2294-2302.
28. Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS. 1994; 8: 283-295.
29. Gami B, Kubba F, Ziprin P. Human Papilloma Virus and Squamous Cell Carcinoma of the Anus. Clin Med Insights Oncol. 2014; 8: 113-119.
30. Meulendijks D, Tomasoa NB, Dewit L, Smits PH, Bakker R, van Velthuysen ML, Rosenberg EH, Beijnen JH, Schellens JH, Cats A. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br J Cancer. 2015; 112: 1358-1366.
31. Martin V, Zanellato E, Franzetti-Pellanda A, Molinari F, Movilia A, Paganotti A, Deantonio L, De Dosso S, Assi A, Crippa S, Boldorini R, Mazzucchelli L, Saletti P, Frattini M. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. Histol Histopathol. 2014; 29: 513-521.